613 related articles for article (PubMed ID: 18310816)
21. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
22. [Bisphosphonate or Raloxifene?: which drug we can choose for osteoporotic patients?].
Miki T; Saito S
Clin Calcium; 2006 Jan; 16(1):167-74. PubMed ID: 16397368
[TBL] [Abstract][Full Text] [Related]
23. [Effects of antiresorptive therapy on the structural and material properties of bone strength].
Kishimoto H
Clin Calcium; 2016 Jan; 26(1):107-15. PubMed ID: 26728537
[TBL] [Abstract][Full Text] [Related]
24. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
Takada J; Iba K; Yamashita T; Yoshizaki T
Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
[TBL] [Abstract][Full Text] [Related]
25. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2010 Mar; 20(3):315-21. PubMed ID: 20190360
[TBL] [Abstract][Full Text] [Related]
26. [Effects of SERMs on bone health. Combination therapy with raloxifene].
Gorai I; Hori H
Clin Calcium; 2010 Mar; 20(3):408-12. PubMed ID: 20190371
[TBL] [Abstract][Full Text] [Related]
27. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis.
Szulc P
Clin Biochem; 2012 Aug; 45(12):907-19. PubMed ID: 22330940
[TBL] [Abstract][Full Text] [Related]
28. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
[No Abstract] [Full Text] [Related]
29. [Assessment of bone quality. Bone quality as the determinant of bone strength].
Mori S
Clin Calcium; 2008 Mar; 18(3):293-9. PubMed ID: 18310815
[TBL] [Abstract][Full Text] [Related]
30. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis.
Seeman E
Osteoporos Int; 2003; 14 Suppl 3():S2-8. PubMed ID: 12730770
[TBL] [Abstract][Full Text] [Related]
31. Exercise and pharmacological countermeasures for bone loss during long-duration space flight.
Cavanagh PR; Licata AA; Rice AJ
Gravit Space Biol Bull; 2005 Jun; 18(2):39-58. PubMed ID: 16038092
[TBL] [Abstract][Full Text] [Related]
32. [SERM and quality of bone].
Sohen S
Clin Calcium; 2004 Oct; 14(10):96-9. PubMed ID: 15577138
[TBL] [Abstract][Full Text] [Related]
33. Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys.
Yamagami Y; Mashiba T; Iwata K; Tanaka M; Nozaki K; Yamamoto T
Bone; 2013 May; 54(1):1-7. PubMed ID: 23356990
[TBL] [Abstract][Full Text] [Related]
34. [Morphological analysis of bone dynamics and metabolic bone disease. Does bisphosphonate treatment cause severely suppressed bone turnover (SSBT) ?].
Kondo N; Yoda T
Clin Calcium; 2011 Apr; 21(4):583-7. PubMed ID: 21447926
[TBL] [Abstract][Full Text] [Related]
35. Current and emerging therapies for osteoporosis.
Mitchner NA; Harris ST
J Fam Pract; 2009 Jul; 58(7 Suppl Osteoporosis):S45-9. PubMed ID: 19825319
[TBL] [Abstract][Full Text] [Related]
36. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
37. Histomorphometric analysis of glucocorticoid-induced osteoporosis.
Dalle Carbonare L; Bertoldo F; Valenti MT; Zenari S; Zanatta M; Sella S; Giannini S; Cascio VL
Micron; 2005; 36(7-8):645-52. PubMed ID: 16243531
[TBL] [Abstract][Full Text] [Related]
38. [Assessment of bone quality. Bone remodeling and bone quality].
Sano G; Matsuo K
Clin Calcium; 2008 Mar; 18(3):315-20. PubMed ID: 18310818
[TBL] [Abstract][Full Text] [Related]
39. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis.
Lyritis GP; Georgoulas T; Zafeiris CP
Ann N Y Acad Sci; 2010 Sep; 1205():277-83. PubMed ID: 20840284
[TBL] [Abstract][Full Text] [Related]
40. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
Bagi CM; Volberg M; Moalli M; Shen V; Olson E; Hanson N; Berryman E; Andresen CJ
Anat Rec (Hoboken); 2007 Aug; 290(8):1005-16. PubMed ID: 17610276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
